Recruiting

TSC-100 & TSC-101

Sponsor:

TScan Therapeutics, Inc.

Code:

NCT06976736

Conditions

AML

ALL

MDS

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Observational

Study Details

Brief summary:

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and efficacy.

Conditions

AML

ALL

MDS

Study ID

NCT06976736

Start date

Sep 9, 2025

Status verified date

Sep, 2025

Completion date

Sep, 2040

Anticipated

Primary completion date

Sep, 2040

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants who received a TCR-T cellular therapy in a clinical study sponsored by TScan Therapeutics.
  • Signed informed consent.

Exclusion Criteria:

  • None

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational

No study drug will be administered during this trial. Participants previously treated with TSC-100 or TSC-101 in a TScan study will be evaluated for long-term safety and efficacy.

Interventions

Observational

Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products

Primary outcome measure

  • Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) [ Time Frame: 15 years post TCR-T administration ]

Central Contacts and Locations

Central contacts

Madhavi Desai

(857) 399-9832medicalaffairs@tscan.com

Locations

City of Hope

Recruiting

Duarte, California, United States, 91010

Principal Investigator:

Monzr M Al Malki, MD

Mount Sinai

Recruiting

New York, New York, United States, 10029-6696

Principal Investigator:

Alla Keyzner, MD

More Information

Sponsor

TScan Therapeutics, Inc.

Last update posted

Sep 10, 2025

Last verified

Sep, 2025

Keywords

  • TSCAN
  • Cell Therapies
  • TCR-T Cell Therapy
  • Long Term Follow-Up (LTFU)
  • TSC-101
  • TSC-100
  • TSCAN-001

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by TScan Therapeutics, Inc. on 2025-09-10.